These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 35428358)

  • 1. Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology.
    Adib E; Nassar AH; Abou Alaiwi S; Groha S; Akl EW; Sholl LM; Michael KS; Awad MM; Jӓnne PA; Gusev A; Kwiatkowski DJ
    Genome Med; 2022 Apr; 14(1):39. PubMed ID: 35428358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer.
    Sacher AG; Dahlberg SE; Heng J; Mach S; Jänne PA; Oxnard GR
    JAMA Oncol; 2016 Mar; 2(3):313-20. PubMed ID: 26720421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of multigene panel next-generation sequencing in routine clinical practice for identifying genomic alterations in newly diagnosed metastatic nonsmall cell lung cancer.
    Nindra U; Pal A; Bray V; Yip PY; Tognela A; Roberts TL; Becker TM; Williamson J; Farzin M; Li JJ; Lea V; Hagelamin A; Ng W; Wang B; Lee CS; Chua W
    Intern Med J; 2024 Apr; 54(4):596-601. PubMed ID: 37713593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapeutic options in early and metastatic NSCLC-overview.
    Gálffy G; Morócz É; Korompay R; Hécz R; Bujdosó R; Puskás R; Lovas T; Gáspár E; Yahya K; Király P; Lohinai Z
    Pathol Oncol Res; 2024; 30():1611715. PubMed ID: 38605928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
    Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases.
    Huang RSP; Harries L; Decker B; Hiemenz MC; Murugesan K; Creeden J; Tolba K; Stabile LP; Ramkissoon SH; Burns TF; Ross JS
    Oncologist; 2022 Oct; 27(10):839-848. PubMed ID: 35598205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
    Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
    Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular alterations in non-small cell lung carcinomas of the young.
    VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
    Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice.
    Cho BC; Loong HHF; Tsai CM; Teo MLP; Kim HR; Lim SM; Jain S; Olsen S; Park K
    Curr Oncol; 2022 Mar; 29(3):2154-2164. PubMed ID: 35323374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additional impact of genetic ancestry over race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancer.
    Wang X; Hou K; Ricciuti B; Alessi JV; Li X; Pecci F; Dey R; Luo J; Awad MM; Gusev A; Lin X; Johnson BE; Christiani DC
    HGG Adv; 2024 Jul; 5(3):100320. PubMed ID: 38902927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
    Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
    Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
    Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers.
    Chapman AM; Sun KY; Ruestow P; Cowan DM; Madl AK
    Lung Cancer; 2016 Dec; 102():122-134. PubMed ID: 27987580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers.
    Varghese AM; Sima CS; Chaft JE; Johnson ML; Riely GJ; Ladanyi M; Kris MG
    J Thorac Oncol; 2013 Jan; 8(1):123-5. PubMed ID: 23242442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers.
    Jiagge E; Jin DX; Newberg JY; Perea-Chamblee T; Pekala KR; Fong C; Waters M; Ma D; Dei-Adomakoh Y; Erb G; Arora KS; Maund SL; Njiraini N; Ntekim A; Kim S; Bai X; Thomas M; van Eeden R; Hegde P; Jee J; Chakravarty D; Schultz N; Berger MF; Frampton GM; Sokol ES; Carrot-Zhang J
    Cancer Cell; 2023 Nov; 41(11):1963-1971.e3. PubMed ID: 37890492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond tobacco: genomic disparities in lung cancer between smokers and never-smokers.
    Garrido J; Bernal Y; González E; Blanco A; Sepúlveda-Hermosilla G; Freire M; Oróstica K; Rivas S; Marcelain K; Owen G; Ibañez C; Corvalan A; Garrido M; Assar R; Lizana R; Cáceres-Molina J; Ampuero D; Ramos L; Pérez P; Aren O; Chernilo S; Fernández C; Spencer ML; Aguila JF; Dossetto GB; Olea MA; Rasse G; Sánchez C; de Amorim MG; Bartelli TF; Nunes DN; Dias-Neto E; Freitas HC; Armisén R
    BMC Cancer; 2024 Aug; 24(1):951. PubMed ID: 39097719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
    Ke L; Xu M; Jiang X; Sun X
    Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.
    Scheffler M; Ihle MA; Hein R; Merkelbach-Bruse S; Scheel AH; Siemanowski J; Brägelmann J; Kron A; Abedpour N; Ueckeroth F; Schüller M; Koleczko S; Michels S; Fassunke J; Pasternack H; Heydt C; Serke M; Fischer R; Schulte W; Gerigk U; Nogova L; Ko YD; Abdulla DSY; Riedel R; Kambartel KO; Lorenz J; Sauerland I; Randerath W; Kaminsky B; Hagmeyer L; Grohé C; Eisert A; Frank R; Gogl L; Schaepers C; Holzem A; Hellmich M; Thomas RK; Peifer M; Sos ML; Büttner R; Wolf J
    J Thorac Oncol; 2019 Apr; 14(4):606-616. PubMed ID: 30605727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency and functional characterization of fusion genes in squamous cell carcinoma of the lung.
    Alidousty C; Becker A; Binot E; Hillmer AM; Merkelbach-Bruse S; Budde B; Bäßmann I; Rappl G; Wolf J; Eich ML; Noh KW; Buettner R; Schultheis AM
    Gene; 2024 Feb; 895():148018. PubMed ID: 37981082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.